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Glutathionylation potentiates benign
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Dissociation of superoxide dismutase 1 dimers is enhanced by glutathionylation, although the dissociation
constants reported to date are imprecise. We have quantified the discreet dissociation constants for
wild-type superoxide dismutase 1 and six naturally occurring sequence variants, in their unmodified and
glutathionylated forms, at the ratios expressed. Unmodified superoxide dismutase 1 variants that shared
similar dissociation constants with SOD1WT had disproportionately increased dissociation constants when
glutathionylated. This defines a key role for glutathionylation in superoxide dismutase 1 associated familial
amyotrophic lateral sclerosis.
A
pproximately one in five cases of familial amyotrophic lateral sclerosis (fALS) is due to naturally occurring
mutations in the gene encoding superoxide dismutase 1 (SOD1)1. Over 150 such mutations have been
reported to occur, and these mutations can occur at virtually any residue of the primary sequence. Many of
these mutations confer a significant level of instability upon the native dimer, which may ultimately unfold and
form insoluble cytoplasmic aggregates - a hallmark of SOD1 associated fALS pathology2. Recently, evidence has
emerged to suggest that SOD1WT aggregation is also involved in some cases of the considerably more prevalent
sporadic ALS3–5.
The prevailing hypothesis of SOD1 aggregation suggests that dissociation of the native homodimer is a key
step, as SOD1 monomers have been identified as a common misfolding intermediate6,7. This mechanism is
supported by the extraordinary difference in dissociation constant (KD) reported for the SOD1A4V dimer
(3 mM)8, compared with SOD1WT (2.25 nM)9; i.e. the dissociation of SOD1A4V into monomers is approximately
1000 times more facile at concentrations found in vivo. Furthermore, chemical cross-linking of the aggregation
prone variant, SOD1A4V can prevent its aggregation in vitro8, while cross-linking of other mutants conferred
greater thermostability10.
A compounding factor in SOD1 dissociation is the post-translational modification (PTM) of Cys111 by the
ubiquitous antioxidant, glutathione (GSH), which has been demonstrated as being the dominant PTM in human
tissue9 (Fig. 1a; Fig. S1a). Similar to many residues in the primary chain of SOD1, Cys11111 is proximal to the
dimer interface and, not surprisingly, the introduction of GSH has been proposed to augment dissociation11. We
explored this hypothesis for a set of human SOD1 variants with well-defined and broad ranging rates of disease
progression; from 1.2 years survival post-onset for SOD1A4V, to approximately 17.6 years for SOD1H46R.
Results
Our initial assay, using mass spectrometry, revealed that all variants were glutathionylated to some extent when
produced in E. coli, from a low of 3% for SOD1V148G to 36% for SOD1A4V (Fig. 1a). When these data were arranged
in order of disease progression, a plausible correlation was evident for SOD1A4V, SOD1G93A, SOD1G37R and
SOD1H46R; however substantial glutathionylation of non-pathogenic SOD1WT compared to the aggressive variant
SOD1V148G, suggested that this modification alone is not predictive of disease progression. Indeed, while the
sequence of these SOD1 variants may determine their susceptibility to glutathionylation, further work is required
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To compare the relative dissociation propensity of our SOD1 var-
iants, we performed nanoelectrospray-ionization mass spectrometry,
with conditions optimized to preserve solution phase structures dur-
ing ionization and subsequent in vacuo detection12 (Fig. 1b; Fig. S2).
Each of the SOD1 variant spectra exhibited peaks arising from two
dominant ion populations at ,2900 m/z and ,3200 m/z, corres-
ponding to the 101 and 111 ions of their respective dimers. Only
minor peaks were observed for the 91 and 121 charge states, indi-
cating that the dimers had negligible variation in their tertiary and
quaternary structures. On closer inspection, a series of three maxima
were identified within the 101 and 111 peaks, arising from dimers
composed of; (i) two unmodified SOD1 (uSOD1) monomers; (ii)
uSOD1 paired with gsSOD1; (iii) two gsSOD1 monomers. With
the exception of SOD1A4V, monomers were significantly less abund-
ant than dimers, but similarly confined to two (71 and 81) charge
states (Fig. 1b & inset). For all variants, the most abundant monomer
observed was gsSOD1 (Fig. 1c), even though uSOD1 constituted the
majority of total protein.
The mixture of SOD1 dimers was further interrogated using tan-
dem mass spectrometry to isolate an ion population exclusive to the
dimer (D111), prior to collision-induced dissociation (CID). At the
minimum accelerating voltage (6 V) required to traverse an argon-
filled CID region, the spectrum contained a single large peak of
isolated D111 ions (Fig. S3a). At an accelerating potential of 20 V,
two additional peaks arose at ,2700 m/z and 3200 m/z, being due to
the dissociation of D111 into charge-complementary M51 and M61
monomers. These peaks increased in intensity at 40 V and 60 V,
after which the more asymmetric dissociation pathway via M41
and M71 monomer ions became competitive. This hierarchical gas-
phase molecular division, based on charge, was also observed for
gsSOD1 (Fig. S3b). We compared the M61 abundance for uSOD1
and gsSOD1 under low (10 V) versus high (70 V) energy CID con-
ditions: at 10 V, gsSOD1A4V, gsSOD1G93A and gsSOD1G37R had a
greater proportion of M61 than uSOD1 indicating that less energy
is required to remove gsSOD1 monomer from the dimer than
uSOD1. A comparison of the spectra at 70 V versus 10 V shows that
gsSOD1:uSOD1 is larger at low energy CID for all seven proteins,
which supports the hypothesis that modification by glutathione
destabilizes the dimer.
A caveat to the gas-phase analysis of molecular interactions is the
absence of bulk water which, to varying degrees, can affect the
strength of non-covalent association between proteins13. Thus, it
was possible that the more facile removal of gsSOD1 from the gas-
phase dimer (Fig. 1b&c) is not necessarily reflective of the aqueous
environment found in vivo. To address this uncertainty, we prepared
dilution series of the SOD1 variants ranging from 20 mM down to
625 nM, prior to mass analysis using identical instrument conditions
for all samples. The spectra acquired at each concentration provided
a snapshot of all species present in solution and so, by plotting the
proportion of monomer versus concentration (Fig. 2a; Fig. S4), we
were able to calculate discreet dissociation constants for (uSOD1)2
and (gsSOD1)2 (Table 1; Fig. 2b). Unlike the homodimers, which
dissociate into their respective and unique monomer pairs, products
of the mixed dimer (uSOD1:gsSOD1) contributed to both popula-
tions of monomer, and were not so readily estimated. In an effort to
account for monomers originating from the mixed dimer, we mon-
itored the decline in (uSOD1:gsSOD1) 111 ion intensity with success-
ive dilution, and subtracted an equivalent quantity from each
monomer signal. Although imprecise, we believe this correction atte-
nuated, to some extent, the confounding effects of the mixed dimer
species.
All uSOD1 variants had KD values greater than uSOD1WT (9 6
1 nM), implying that these single residue substitutions are suf-
ficient to disturb the quaternary structure (Table 1). The most
substantial augmentation was observed for uSOD1A4V (1.1 6






































































































































Figure 1 | Mass spectrometry analysis of SOD1 variants. (a) Percentage of
recombinantly expressed SOD1 that was glutathionylated (yellow), as
determined by the area under the peaks of MS spectra, compared to disease
progression (grey), expressed in truncated life years as loge[(75 2 (25 1
d)], where d equals the reported average disease duration, assumed life
expectancy is 75 years and age at onset of disease is set to 50 years. (b) Mass
spectrum of native SOD1WT (main) and SOD1A4V (faint) with species
charge states labeled (D 5 dimer, M 5 monomer). Additional maxima
within the peaks are the result of glutathionylation of one or both subunits
to give a mixed (*) or gsSOD1(**) dimer. Inset shows the ratio of dimer to
monomer for the two proteins, derived from charge state peak areas in the
spectrum. (c) Expansion of the M71 region showing peaks corresponding
to uSOD1 (red) and gsSOD1 (yellow). (d) The percentage of gsSOD1
monomer (yellow) compared to disease progression (grey) for all SOD1
variants. The gsSOD1 measurements were performed in triplicate and
error bars represent standard error of the mean.
www.nature.com/scientificreports
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whereas uSOD1G93A (12 6 1 nM) had a KD only marginally higher
than uSOD1WT. Significantly, the KD value of each gsSOD1 species
was higher than the corresponding uSOD1, with the largest (13-
fold) increase observed for gsSOD1G93A, followed by gsSOD1A4V (9-
fold), gsSOD1G37R (6-fold) and gsSOD1WT (4-fold) (Table 1). There
was insufficient gsSOD1V148G and gsSOD1D90A to accurately cal-
culate their KD values.
Discussion
Glutathionylation of SOD1 expressed in E. coli, has previously been
reported to occur at each of the four cysteine residues (Cys6, Cys57,
Cys111, and Cys146) as detected by mass spectrometry14. Contra-
stingly, our analysis of recombinant SOD1WT demonstrated that no
more than one glutathione was bound per subunit, and this was the
case for all SOD1 variants in this study (Fig. S1). This discrepancy
stems from the protocol used by Furukawa and coworkers14, which
directed expression of SOD1 into inclusion bodies or soluble apo-
proteins followed by refolding and metal enrichment after extraction
from bacterial cells15. In the present work, SOD1 was co-expressed
with the yeast-copper-chaperone for SOD1 (yCCS) in the presence of
copper and zinc, with subsequent purification of soluble SOD1 from
the bacterial cytosol16. The yCCS facilitates folding of the nascent
chain, and formation of the disulfide bond between Cys57 and
Cys14614. This disulfide effectively locks the b-barrel structure, ren-
dering these Cys residues inaccessible to larger molecules; ipso facto,
unlikely sites of glutathionylation. Furthermore, it has been demon-
strated that Cys6 is buried inside the b-barrel of catalytically active
SOD1, i.e., inaccessible to aqueous reductants17. We assessed the
dismutase activity of our variants using in-gel zymography, which
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Figure 2 | SOD1 monomer abundance increases with dilution. (a) of SOD1 variants showing changes in the proportion of monomeric uSOD1 (red) and
gsSOD1 (blue) as a function of protein concentration: (i) SODWT, (ii) SOD1A4V, (iii) SOD1G37R, (iv) SOD1H46R, (v) SOD1D90A, (vi) SOD1G93A, (vii)
SOD1V148G. Analyses were performed in triplicate at each concentration and error bars represent standard deviation about the mean. (b) Relationship
between disease duration and KD for uSOD1 (red) and gsSOD1 (blue).
Table 1 | SOD1 dissociation constants as determined by native mass spectrometry. The dissociation constants are means 6 standard error
from 3 distinct data sets with each containing 5 data points (see supplementary figure 4)
Variant WT A4V G37R H46R D90A G93A V148G
SOD1 KD
(nM)
9 6 1 1100 6 100 10 6 1 30 6 4 25 6 4 12 6 1 271 6 40
GS-SOD1 KD
(nM)
34 6 5 9600 6 900 60 6 9 97 6 16 - 160 6 32 -
www.nature.com/scientificreports
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SOD1H46R (Fig. S1b). Therefore, although we did not explicitly dem-
onstrate Cys111 to be the site of our observed glutathionylation, it is
inferable that the only cysteine residue sufficiently exposed and
therefore substantially modified by glutathione was Cys111.
It is well documented that patients suffering from SOD1-assoc-
iated fALS have variable survival times, dependent upon the particu-
lar amino acid mutation18. Considering the role played by dimer
dissociation, as an entrée to aggregation, we scrutinized our data
for evidence of a link between patient survival and KD (Fig. 2b).
For uSOD1, the KD values were poorly associated with disease dura-
tion (R2 5 0.58), primarily due to the outlier characteristics of
uSOD1G93A. In contrast, KD values for gsSOD1 showed a much stron-
ger correlation (R2 5 0.79), indicating that glutathionylation may be
responsible for the disparity between perceived SOD1 stability and
observed patient survival. Consider the G93A mutation. This is
reported as having little effect upon dimer dissociation19, and our
results for the KD of uSOD1G93A confirm this (Fig. 3a); yet the survival
time of patients carrying this mutation is, on average, a mere 2.2
years. Our ability to distinguish between, and calculate separate KD
values for uSOD1 and gsSOD1 resolves this apparent inconsistency -
the KD of gsSOD1G93A is 13 times higher than that of uSOD1 (Fig. 3b;
Table 1) - highlighting the significance of this methodology.
Our data can be used to reframe the original hypothesis in more
specific terms: i.e., it is not only (the extent of) SOD1 glutathionyla-
tion that influences the rate of disease progression, but also the KD of
the glutathionylated species. Glutathionylation, however, is not a
requirement for pathogenicity, as sequence modification alone of
SOD1V148G causes a 30-fold increase in KD over SOD1WT. Similarly,
our extracted KD value for uSOD1A4V reflects the considerable instab-
ility of this non-glutathionylated species. These mutations are
located deep in the inter-subunit cleft, where small molecular volume
changes are able to disrupt the dimer interface leading to more facile
dissociation20 (Fig. S5).
In contrast to Val148 and Ala4, Gly37 and Gly93 are spatially
remote to the dimer interface, being situated in the b3/b4 Greek
key loop and b5/b6 inter-strand loop respectively (Fig. S5). It is
notable that these loops are proximal to each other and the Leu38
cork, while Cys111 is within the b6/b7 Greek key loop at the opposite
end of the b-barrel. Prior to glutathionylation, the individual muta-
tions G37R and G93A impart negligible effect upon the KD of SOD1;
i.e., in isolation, these mutations are not pathologically destabilizing
(Table 1). Rather, it is the synergy of glutathionylation and point
mutation at the b-barrel ‘poles’ that accounts for the significantly
higher KD values reported in this study, and presumably, the malig-
nance of these variants in vivo. It stands to reason then, that glu-
tathionylation of SOD1 alters the KD of a multitude of individual
variants in a unique, allosteric-like fashion, and that it is the com-
bination of KD(uSOD1) and KD(gsSOD1) (Fig. 3c) which impact the patho-
genicity of the protein. Therefore, we propose an elaboration to the
contemporary notion in which SOD1 dissociation is the primary
underlying cause of SOD1 fALS.
Specifically, dissociation of the SOD1 dimer is a biophysical con-
sequence of either, (i) a potent destabilizing mutation such as A4V,



































































































































































Figure 3 | The profound effect of glutathionylation on SOD1 dissociation constants. Histograms comparing KD values of (a) uSOD1, (b) gsSOD1,
and (c) uSOD1 1 gsSOD1, to disease progression (grey). (d) A scheme of the proposed factors affecting SOD1 dimer dissociation. Briefly, dimer
dissociation occurs due to mutation, glutathionylation, and cellular stresses. The increased monomer population is more likely to unfold and increase
cellular stress. Glutathione (GSH) levels in the cell are elevated during periods of oxidative stress, thereby increasing the chances of SOD1 becoming
glutathionylated.
www.nature.com/scientificreports
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such as G93A. Consequently, there is a twofold increase in the
abundance of monomers, which are more susceptible to misfold into
toxic conformations compared to the dimer6,7 (Fig. 3d). If the cellular
clearance rate of misfolded SOD1 is inadequate, increasingly fre-
quent hydrophobic interactions ultimately give way to aggregation,
forming larger amorphous structures that stress the cellular
machinery21. Many neurodegenerative diseases, including ALS are
also associated with oxidative stress22, which in turn can lead to an
up-regulation of glutathione23. Indeed, an increase in GSH has been
observed in ALS patient CSF24. Analysis of human tissue from ALS
patients, and in cell experiments, are currently under way to further
investigate the role of glutathionylation in SOD1 associated fALS.
Methods
Materials. All solutions were prepared using Milli-Q ultra-purified water using the
Millipore purification system (Massachusetts, USA). All materials were of analytical
grade. Tryptone, Tris-base, DTT, b-mercaptoethanol, bromophenol blue, brilliant
blue, ammonium persulphate, SDS, ampicillin sodium salt, and IPTG were from
Amresco (Ohio, USA). NaCl, ammonium sulphate, agar, acetonitrile, Tris-HCl,
tetramethylethylenediamine, ammonium acetate and RNase were from Sigma-
Aldrich (Missouri, USA). DNase was from Roche Diagnostics (NSW, Australia).
Carbenicillin was from Carbenicillin Direct (UK). Copper sulphate pentahydrate was
from Ace Chemical Company (SA, Australia). Zinc sulphate heptahydrate was from
Hopkin and Williams LTD (Birmingham, UK). Formic acid and acetic acid were from
Univar (NSW, Australia). Methanol was from Ajax Finechem (NSW, Australia). Gold
coated borosilicate electrospray capillaries were made in-house.
Expression and purification of recombinant SOD1. Plasmids encoding SOD1WT,
SOD1A4V, SOD1G37R, SOD1H46R, SOD1D90A, SOD1G93A, and SOD1V148G were a gift from
the Oliveberg Group (Sweden). Protein expression and purification were performed
according to16. Briefly, the SOD1 plasmids were transformed into chemically
competent BL21* E. coli using heat shock. Following transformation, the protein was
expressed in the presence of copper and zinc ions with the addition of IPTG. The
expressed SOD1 was purified via size exclusion chromatography (Hiload 16/60
Superdex 75 PG, GE USA) and anion exchange chromatography (Hiscreen Capto-Q,
GE USA).
Sample preparation for mass spectrometry. SOD1 samples were desalted and buffer
exchanged into 200 mM NH4OAc (pH 7), using gel filtration chromatography
(Superdex 200 10/300 GL, GE USA). Briefly, SOD1 samples were concentrated to
20 mg/ml and 100 ml was loaded onto the column at a flowrate of 0.4 mg/ml. The
concentration of SOD1 was determined at 265 nm using a UV/Vis
spectrophotometer, and a molar extinction coefficient of 18 700 M21cm21 25.
Mass spectrometry. SOD1 samples in 200 mM NH4OAc were denatured using
formic acid and acetonitrile with the final concentration of each being 10% and 40%
respectively. Mass analyses were performed on a Q-ToF ULTIMA mass spectrometer
(Waters, UK) in positive ion mode with nanoelectrospray source. Instrument
parameters included: capillary 1.5 kV, sample cone 200 V, desolvation gas flow
180 L/h. Native protein analyses were performed in 200 mM NH4OAc on a SYNAPT
G2 HDMS (Waters, UK) in positive ion mode. Instrument parameters were similar to
Ruotolo et al. (2008)26 with the exceptions: capillary voltage 1.5 kV, sample cone
30 V, cone gas 70 L/h, trap collision voltage 6 V, ion-transfer stage pressure 4.15 e21
mbar, ToF analyzer pressure 2.38 e26 mbar. All SOD1 variants were analyzed at a
concentration of 20 mM. For MS/MS experiments, the trap collision energy was
increased from 10 to 100 V in increments of 10 V with 30 scans at each increment.
The dilution series mass spectra were acquired at concentrations of 20, 15, 10, 7.5, 5,
2.5, 1.25 and 0.625 mM with the following instrument parameters: capillary voltage
1.52 kV, sample cone 137 V, cone gas 78 L/h, trap collision voltage 16 V, transfer CE
8 V, ion transfer stage pressure 3.72 e24 mbar, ToF analyser pressure 9.01 e27 mbar,
backing pressure 4.0 e0 mbar. All mass spectra in this study were externally calibrated
using a solution of cesium iodide (10 mg/ml in water) and were processed using
Masslynx 4.1 software (Waters, UK).
Dissociation constants. Dissociation constants were derived from the mass
spectrometry data using the method of Rose et al., (2011)27. Briefly, the intensity, as
determined by the area under the peak, of all peaks relating to SOD1 monomers (Mi)
and dimers (Di) were summed to give total signal intensity (ITS):
IMzID~ITS ð1Þ
The proportion of monomer signal (PM) was determined by dividing the intensity of
the monomeric species (IM) by the total signal intensity (ITS):
IM=ITS~PM ð2Þ
The concentration of monomer at equilibrium ([M]eq) was determined by
multiplying the proportion of monomer signal (PM) by the total protein
concentration in mM as determined by UV/Vis spectroscopy ([Po]):
PM| Po½ ~ M½ eq ð3Þ
The concentration of dimer at equilibrium ([D]eq) is defined as:
Po½ { M½ eq
 .
2~ D½ eq ð4Þ
The KD was derived from the gradient of the plot of [D]eq against [M]2eq (fitting
performed with Prism 5.0, GraphPad Software, Inc.) In each case at least 5 data points
were plotted with repeat experiments being performed if the line of best fit gave least-
squares-regression, R2 , 0.75.
Statistical analysis. Statistical analyses were carried out using Prism 5.0 software
(Graphpad). All mass analyses were performed in triplicate (n 5 3) with error bars
representing the standard error of the mean. The dissociation plots (Figure 2) were
fitted with a Log (Gaussian) function. The KD plots (Fig. S4) were fitted using linear
regression.
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